Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2/3 2Phase NA 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1

Conditions

Pheochromocytoma 1Pain, Intractable 1Obesity 1Non-functioning Pituitary Adenoma 1Neoplasms 1Nausea 1Intrathecal Dexmedetomidine 1Dyspnea 1Delirium 1Death 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Dexmedetomidine × Clear all
NCT01687751 2015-05-25

Pilot Study Comparing Treatment With Dexmedetomidine to Midazolam for Symptom Control in Advanced Cancer Patients

Fraser Health

Phase 2 Withdrawn
Other

Death, Delirium, Dyspnea, Nausea, Neoplasms, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡